Aleksandra D. Shutova

Aleksandra D. Shutova

Auto-generated profile, based on publicly available information

Aleksandra D. Shutova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
IKIrina I. Kalinina
Irina I. Kalinina
KAKhristina S. Antonova
Khristina S. Antonova
PAPavel Avdonin
Pavel Avdonin
EKElizaveta E. Klebanova
Elizaveta E. Klebanova
NKNatalia N. Kotskaya
Natalia N. Kotskaya
AMAlexey A. Maschan
Alexey A. Maschan
Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown to rapidly restore platelet numbers and reduce the risk of severe end-organ damage when added to plasma exchanges (PEXs) and immunosuppression (IST). Here, we report the outcomes in 3 children with aTTP who were treated with caplacizumab in combination with PEXs and IST. In all 3 patients, platelet count increased to >15,000/mm3 in 24 h and normalized on day 4, whereas normalization of ADAMTS13 activity >50% and elimination of the inhibitor was achieved after 18 to 89 days. Epistaxis was observed in 2 patients and was the only side effect related to caplacizumab. Caplacizumab is a promising agent for first-line treatment of children with aTTP.

28 December 2023 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
ASA. D. Shutova
A. D. Shutova
IKI. I. Kalinina
I. I. Kalinina
ESE. V. Suntsova
E. V. Suntsova
ERE. V. Raikina
E. V. Raikina
GGGennadiy Galstyan
Gennadiy Galstyan
AMA. A. Maschan
A. A. Maschan
Introduction. Congenital thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening genetic disorder characterized by recurrent episodes of microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction due to the defi ciency or dysfunction of the ADAMTS13 enzyme. Despite the availability of clinical and laboratory diagnostic criteria the diagnosis remains challenging due to a wide range of diseases with similar appearance.Aim: to analyze the clinical manifestations and treatment results of identifi ed cases of congenital TTP at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.Methods. This article reviews 11 clinical cases with congenital TTP genetically confi rmed or with typical clinical and laboratory signs.Results. Clinical and laboratory signs of TTP are highly variable and nonspecifi c, which was observed in the described cohort of patients. One of the trigger factors is often an acute respiratory viral infection, and stabilization of the disease can occur after transfusions of blood components. A delay of diagnosis can often lead not only to a delay of correct therapy, but also to the prescription of wrong therapy. The main diagnosis confi rmatory method was a molecular genetic test, which was carried out in 8 cases. All patients diagnosed with congenital TTP were successfully treated with FFP therapy.Conclusion. Early diagnosis of TTP is diffi cult due to the lack of specifi c clinical manifestations and easily accessible laboratory tests

12 July 2021 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
TUT. L. Ushakova
T. L. Ushakova
ETE. A. Tuzova
E. A. Tuzova
ASA. D. Shutova
A. D. Shutova
OGO. V. Gorovtsova
O. V. Gorovtsova
TGT. G. Gasparyan
T. G. Gasparyan
VPV. G. Polyakov
V. G. Polyakov
Introduction. Standard eye enucleation (EE) may not always guarantee a sufficient length of resection of the optic nerve (ON) so that the tumor cells do not spread along the optic nerve at the intersection line. Surgical access and the scope of surgical intervention are determined by the spread and localization of the tumor, as well as the qualification of the operating team.Purpose— to evaluate the role of extended surgical interventions in the spread of extraocular tumors on the ON.Materials and methods. The study included 9 patients with retinoblastoma (RB) and macroinvasion of the ON during primary magnetic resonance imaging (MRI) and/or micromorphological invasion of the ON resection line after EE. 4 of the 9 patients were treated with primary/secondary EE, induction chemotherapy (CT) and high-dose CT (HDCT), radiation therapy (RT). 5 out of 9 patients underwent secondary extended surgical interventions: exenteration of the orbit (n = 1), osteoplastic lateral orbitotomy with precanal resection of the ON (n = 2) in combination with EE in one case, subfrontal craniotomy (n = 1) and orbitozygomatic craniotomy (n = 1) with prechiasmal resection of the ON and EE with adjuvant RT (excluding the latter case) and CT, without HDCT.Results. It should be noted that the overall survival (OS) of 5 patients with complete microscopic resection (R0) after extended secondary operations was 75 ± 0.217 % with an average follow-up period of 77.25 ± 18.8 months, while in 4 patients with R1 (n = 4) without secondary extended operations with HDCT reached only 50 ± 0.25 % with an average follow-up period of 57 ± 24.8 months.Conclusion. MRI is mandatory for the primary diagnosis of RB, especially when there is a risk of the tumor spreading through the ON. Secondary surgery with R0-resection has a positive effect on survival. The need for adjuvant RT and CT after surgery should be discussed.

14 February 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DED. A. Evstratov
D. A. Evstratov
ASA. D. Shutova
A. D. Shutova
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
SRS. A. Radygina
S. A. Radygina
YAYu. G. Abugova
Yu. G. Abugova
ЮДЮ. Ю. Дьяконова
Ю. Ю. Дьяконова
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse treatment is directly dependent on whether or not a tumor clone has been completely eradicated before hematopoietic stem cell transplantation (HSCT). Immunotherapy made it possible to achieve minimal residual disease (MRD) – negative remission even in refractory patients. One example of such immunotherapeutic agents is inotuzumab ozogamicin (InO), an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent calicheamicin. We included 17 patients under the age of 18 with relapsed or refractory precursor B-cell ALL (pre-B ALL) who had been treated with InO at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia from 01.10.2016 to 01.09.2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The efficacy of the therapy was assessed based on the patients’ morphological response, MRD negativity and overall survival. Treatment toxicity was assessed according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). Statistical analysis was performed using the XLSTAT 2016 software. The majority of the patients (75%) responded to the therapy. MRD negativity was achieved in 41.2% of the study patients. The one-year overall survival rate was 40.3% (95% confidence interval 14.8–65.7). The treatment was well tolerated but 33% of the patients treated with standard-dose InO and subsequent HSCT developed veno-occlusive disease/sinusoidal obstruction syndrome. In our study, we demonstrated the high efficacy of InO both when used as a rescue therapy in patients with relapsed/refractory pre-B ALL and as a bridging therapy in patients before HSCT.

29 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MUMarina Utkina
Marina Utkina
ASAnastasia Shcherbakova
Anastasia Shcherbakova
Ruslan DeviatiiarovRuslan Deviatiiarov
Ruslan Deviatiiarov
ARAlina Ryabova
Alina Ryabova
MLMarina Yu Loguinova
Marina Yu Loguinova
SPSergey Popov
Sergey Popov
Current scRNA-seq studies of solid tissues mostly rely on enzymatic dissociation of fresh samples or the fallback on nuclei isolation from frozen or partially fixed samples. However, due to the complex tissue organization or cell fragility, it could be challenging to apply these approaches to the sensitive endocrine tissues. That is, dissociating intact cells from such problematic fresh-frozen samples routinely collected by biobanks remains challenging. In this study, we adapted the acetic-methanol dissociation method – ACME High Salt (ACME HS) to effectively isolate intact single cells from fresh-frozen endocrine tumor samples, including adrenal gland neoplasms, thyroid carcinomas, and pituitary neuroendocrine tumors. We compared the ability of enzymatic, ACME HS, and nuclear isolation methods to preserve the integrity of major cell types and gene expression across 41 tissue samples of different origins. We demonstrated that ACME HS simultaneously dissociates and fixes cells, thus preserving morphology and a high RNA integrity number in problematic cell types. This finding renders the ACME HS dissociation method a valuable alternative in scRNA-seq protocols for challenging tissues where obtaining live cell suspension is difficult or impossible.

28 March 2024 in Acta medica Eurasica
Verified
Journal Article
Closed access
YSYuriy A. Shifrin
Yuriy A. Shifrin
ETElizaveta A. Tuzova
Elizaveta A. Tuzova
AMAnna A. Mahrova
Anna A. Mahrova
ASAlexandra D. Shutova
Alexandra D. Shutova
DBDmitry Blinov
Dmitry Blinov
AKAleksandr I. Karachunskiy
Aleksandr I. Karachunskiy
Acute lymphoblastic leukemia is the most common pediatric cancer. The effectiveness of modern therapy protocols makes it possible to cure over 80% of children, and one of the advanced treatment methods is the use of monoclonal antibodies. Using the example of adult patients in the United States, the economic effectiveness of this innovative treatment strategy was proven, while no similar studies have been conducted in children with primary acute lymphoblastic leukemia. The aim of the study was to determine the real cost of therapy for children and adolescents with acute lymphoblastic leukemia according to the protocol using combined chemotherapy and immunotherapy at the stages of induction and consolidation. Materials and methods. The study included data from 54 patients (the study group) who received therapy using this method, taking into account indicators of direct medical and non-medical costs. The control group included 54 patient models corresponding to the initial estimated parameters when planning the protocol (body weight 30 kg, body surface area 1 m2). Research results. The median of real cost for providing medical care to one patient in the study group was 22% lower than the estimated cost. In its structure, the values of the median costs for inpatient stay, for instrumental and laboratory studies, as well as for drug therapy turned out to be lower. Since younger patients were included in the study group, the cost of drug therapy was recalculated to the calculated patient model, which equalized the median cost of drug therapy for the study and control groups. In a situation with equal characteristics of patients, as well as with the same cost of a day of inpatient stay, the median real cost of providing medical care to one patient in the study group corresponded to the estimated values. Conclusions. The median cost of medical care for patients with acute lymphoblastic leukemia according to the protocol using combined chemotherapy and immunotherapy in the study group was 22% lower than the estimated values. The actual practice of using the protocol for an average patient model with an equal cost of inpatient stay fully corresponded to the estimated values of the protocol.